Catheter Precision - VTAK STOCK NEWS

Catheter Precision (NYSE American:VTAK) has announced its participation in the 30th International Atrial Fibrillation Symposium, scheduled for January 16-18, 2025, in Boston, Massachusetts. The AF Symposium, established in 1995 in response to the growing atrial fibrillation epidemic, has evolved into a significant scientific forum where healthcare professionals can learn about the latest research and therapeutic advances directly from leading investigators.

CEO David Jenkins emphasized that these meetings provide valuable opportunities to showcase their technologies, generate sales leads, and facilitate educational discussions between physicians about their products, studies, and clinical techniques.

Catheter Precision (NYSE American:VTAK) has announced a definitive agreement to acquire PeriKard, through an all-stock transaction. The deal involves issuing 275,000 shares of restricted VTAK common stock for 100% of PeriKard's interests. The closing is expected by the end of January 2025, subject to NYSE/American approval.

PeriKard is developing a specialized kit of tools designed to improve physician access to the heart's pericardial space. The kit aims to provide enhanced needle and drainage systems compared to existing solutions. This technology addresses the clinical need for pericardial access in cases of excess fluid drainage and ablation procedures for treating arrhythmias outside the heart wall.

Catheter Precision (NYSE American:VTAK) has received its first purchase order for LockeT from the southeast region, specifically from The University of Tennessee Medical Center in Knoxville. This development marks the beginning of 2025 and follows the company's recent expansion of its US sales and clinical team for LockeT's national product launch.

The University of Tennessee Medical Center, a 710-bed facility, serves as the region's academic medical center, Magnet® recognized hospital, and Level I Trauma Center. It functions as a major referral center for East Tennessee, Southeast Kentucky, and Western North Carolina, and houses the region's only dedicated Heart Hospital.

Catheter Precision (NYSE American:VTAK) has appointed Philip Anderson as its new Chief Financial Officer, replacing Interim CFO Margrit Thomassen, who will continue as Controller. CEO David Jenkins highlighted Anderson's diverse background in executive management, hedge fund partnership, and investment banking.

Anderson received an inducement award of options to purchase 500,000 shares of Company common stock at $0.53 per share, vesting monthly over three years with a 10-year term. The options were granted under NYSE American listed company manual Section 711(a).

Anderson expressed enthusiasm about joining VTAK, citing the company's position in the growing cardiac electrophysiology market, experienced management team including former Baylis and Boston Scientific executive Marie-Claude Jacques, and two revenue-generating products with strong clinical evidence.

Catheter Precision (NYSE American:VTAK) has received its first purchase order for LockeT from Montefiore Medical Center in the Bronx, NY. This development follows the company's recent expansion of its US sales and clinical team for LockeT's national product launch. Montefiore, a premier academic medical center and primary teaching hospital of Albert Einstein College of Medicine, performs over 1,000 electrophysiology and cardiac rhythm procedures annually. The medical center is part of the Montefiore Einstein health network, which encompasses over 300 locations including 13 hospitals.

Catheter Precision (NYSE American:VTAK) reported Q3 2024 financial results and operational updates. The company has expanded its pipeline to 87 potential hospital customers, with 32 institutions in evaluation phase. Sales revenue reached $96,000 for Q3 and $271,000 for nine months ended September 30. The company reported a Q3 net loss of $4.1 million, with $1.7 million in non-cash charges. Total assets were $26.7 million with $1.3 million cash position. LockeT CE Mark completion is expected by Q1 2025, with European launch planned for Q2 2025. Clinical studies for both LockeT and VIVO products continue to show promising results.

Catheter Precision (NYSE American:VTAK) presented new clinical data from the VIVO EU Registry at the Society of Cardiac Robotic Navigation meeting in Lisbon. Professor Leonor Parreira shared final data from Hospital da Luz, involving 27 subjects, of which 18 underwent ablation procedures. The results showed 100% accurate identification of site origin, approximately 95% successful ablation procedures, and 83% of patients remained arrhythmia-free at 12 months post-ablation. The company plans to publish complete study results including data from seven additional studies.

Catheter Precision (NYSE American:VTAK) has secured $4.9 million in gross proceeds through warrant exercises. The company entered into a definitive agreement for the immediate exercise of Series E, F, G, H, and I warrants to purchase 5,347,981 shares at a reduced price of $0.70 per share, generating $3.7 million. An additional $1.185 million was received through warrant exercises in the past week. In exchange, the company will issue new unregistered Series K warrants for up to 10,695,962 shares at $0.70, exercisable after shareholder approval with a 5.5-year term.

Catheter Precision (NYSE American:VTAK) announced two presentations featuring their VIVO technology at the International Society for Cardiac Robotic Navigation Meeting in Lisbon, Portugal, October 28-29. Dr. Jack Griffiths from Royal Brompton Hospital will present on 'Robotics in VT plus non-invasive 3D mapping', focusing on time-saving data. Peter van Dam, PhD will discuss 'Non-invasive Mapping Using Individual Anatomy', highlighting VIVO's patient-specific advantages. Dr. Leonor Perriera will present updates from the VIVO European Registry, including acute success and 12-month follow-up data for ventricular ablation.